A Single-Center, Open-Label, Prospective Study of a 589/1319 nm Dual Wavelength Laser for the Treatment of Facial Hyperpigmentation.

Abstract

Background: Facial hyperpigmentation, characterized by the excessive production of melanin in the skin, is a prevalent dermatological concern affecting individuals of various ethnic backgrounds.

Aims: To evaluate the safety and efficacy of a multi-wavelength 589/1319 nm dual-pulse duration laser device for the treatment of hyperpigmentation Patients/Methods: A total of 17 healthy women (mean [SD] age of 43.4 [11.6] with skin phototype II-IV) were enrolled in this prospective, single-center study. Eligible participants received up to 3 treatments spaced 3 to 5 weeks apart with 2 follow-up visits at 4 and 12 weeks after the final treatment. Assessments included investigator ratings of skin quality, global aesthetic improvement, and hyperpigmentation. Safety and tolerability were monitored throughout the study.

Results: Significant improvements in hyperpigmentation and skin quality were observed at the 2 follow-up visits from baseline in most patients per investigator assessments. Patient satisfaction was high, and treatments were safe with transient self-resolving side effects such as erythema.

Conclusions: Laser treatments using a dual-wavelength 589/1319nm device significantly improve facial hyperpigmentation in patients of various skin types. J Drugs Dermatol. 2024;23(11):943-947. doi:10.36849/JDD.8196.